David Kravitz is an entrepreneur and inventor who has served in various senior executive, directorship, and advisory positions throughout his career in the life sciences. For over 20 years, his focus has been in the fields of trauma and transplantation medicine, women’s reproductive health, therapeutics adherence, and regenerative medicine. David is a co-inventor of several dozen medical technology patents and is a founder of numerous med tech companies, including Organ Recovery Systems, where he served as Chairman and CEO. In 2004, he was named to Fast Company magazine’s “Fast 50” list of global entrepreneurs/innovators. He presently serves as CEO of Lifeline Scientific, Inc., a company that he co-founded. David has extensive background in mergers and acquisitions, has led companies through international, public, and private institutional financings. Additionally, he has led the development, regulatory approvals, and launches of several global medical technologies, including the market leading LifePort family of solid organ recovery and transport systems. LifePort is a standard of care in clinical transplantation worldwide and has been prominently recognized for its industrial design and engineering. His accomplishments include design excellence awards from the Medical Device and Diagnostic Industry (MDEA Critical Care/Emergency Products category), an exhibition at the Smithsonian Cooper-Hewitt National Design Museum, Popular Science Magazine’s breakthrough technology BOWN Award, and selection into the permanent Collection of The Museum of Modern Art (MoMA) in New York City. David’s medical technology developments in transplantation have been widely studied and published in leading peer reviewed scientific journals including the New England Journal of Medicine. Throughout his career, he has remained active in early childhood education, having founded a Montessori-based preschool in his local community. Also, he is a publisher of books, innovative products, and curriculum in the field of early childhood literacy. David presently serves on the board of directors of several companies in the life sciences.